Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update

Forward-Looking Statements This presentation contains forward-looking

statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's safe harbor

for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, related to Cytokinetics' research and development activities; clinical trial initiation, design, enrollment, conduct,

progress, continuation, completion, timing and results; regulatory submissions, review processes, approval timing and outcomes, including with respect to supplemental applications and approvals in jurisdictions outside the United States; the scope,

expansion, modification, durability or continuation of labeling and promotional claims; commercial readiness, launch timing, market access and reimbursement; anticipated patient, prescriber and payer adoption; expectations regarding market

opportunity, growth and market share; pipeline development and expansion into additional indications or geographies; access to and use of capital; expected future product launch dates for drug candidates, including the probability of clinical

success, receipt of regulatory approval and the timing thereof; and Cytokinetics' business strategy, objectives and future plans. Such statements are based on management's current expectations and assumptions; however, actual results may

differ materially due to various risks and uncertainties, including, but not limited to, uncertainties inherent in drug development and commercialization; the timing, conduct and outcomes of clinical trials; regulatory review and approval processes

in the United States and other jurisdictions; differences in regulatory requirements, labeling, market access or promotional restrictions across jurisdictions; the ability to obtain, expand, maintain or continue desired labeling, promotional claims

or commercial positioning for approved products; potential legal, intellectual property or regulatory constraints affecting commercialization and marketing claims; patient and prescriber acceptance of MYQORZO as compared to alternative therapies;

the availability and terms of reimbursement from commercial and government payers; manufacturing, supply and distribution risks; competition; and the availability of sufficient capital to execute Cytokinetics' business plans. These

forward-looking statements speak only as of the date they are made, and Cytokinetics undertakes no obligation to subsequently update any such statement, except as required by law. For further information regarding these and other risks related to

Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission (the "SEC"). Cytokinetics has filed a registration statement (including a base prospectus) on Form S-3 (File

No. 333- 283576) and will file a preliminary prospectus supplement with the SEC for the offering to which this presentation relates. Before you invest, you should read the base prospectus in that registration statement, the preliminary prospectus

supplement related to the offering (when available) and other documents Cytokinetics has filed with the SEC for more complete information about Cytokinetics and this offering. You may obtain these documents for free by visiting the SEC website at

www.sec.gov. Alternatively, copies of the preliminary prospectus relating to the proposed offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by

email at prospectus@morganstanley.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526 or by email at Prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC,

Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus

Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy these securities,

nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Disclaimer:

The assumptions used in the preparation of this presentation, although considered reasonable by us at the time of preparation, may prove to be incorrect. You are cautioned that the information is based on assumptions as to many factors and that

actual results may vary from the results projected, and such variations may be material. Accordingly, you should not place undue reliance on any forward-looking statements contained herein or rely on them as predictions of future events. The

trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. Certain information contained in this presentation relates to or is based on studies, publications and other data obtained from

third-party sources, as well as our own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the

adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. 2

Our Mission To bring forward new medicines to improve the healthspan of

people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. 3

Now Available FDA-approved for the treatment of adults with symptomatic

oHCM to improve functional capacity and symptoms FDA: U.S. Food & Drug Administration; oHCM: obstructive hypertrophic cardiomyopathy Please see full Prescribing Information, including Boxed WARNING and Medication Guide 4 4

A Commitment to Muscle-Directed Medicines Drug Therapeutic Area Approved

& (Clinical Trial) Research Pre-Clinical Phase 1 Phase 2 Phase 3 Commercialized oHCM* Approved MYQORZO SEQUOIA-HCM in US, China & EU** oHCM (vs. metoprolol) Aficamten MAPLE-HCM Pediatric oHCM Aficamten CEDAR-HCM nHCM Aficamten

ACACIA-HCM HFpEF Ulacamten AMBER-HFpEF Omecamtiv HFrEF Mecarbil COMET-HF Muscular Dystrophy, CK-089 other Research Muscle Biology Directed *MYQORZO is approved for the treatment of adults with symptomatic oHCM to improve functional capacity and

symptoms. Please see full Prescribing Information, including Boxed WARNING and Medication Guide **MYQORZO is only approved in the U.S., China and the EU for the treatment of adults with symptomatic oHCM. Ulacamten, omecamtiv mecarbil and CK-089 are

investigational agents and have not been approved for use by any regulatory agency. Their safety and efficacy has not been established. oHCM: obstructive hypertrophic cardiomyopathy; nHCM: non-obstructive hypertrophic cardiomyopathy; HFpEF: heart

failure with preserved ejection fraction; HFrEF: heart failure with reserved ejection fraction 5

Positioned for Launch & Sustainable Growth COMMERCIAL RESEARCH &

DEVELOPMENT STRONG FINANCIAL POSITION Specialty Muscle-directed platform Cardiology ~$1.1B with multi-program pipeline Franchise cash, cash equivalents & investments (as of 3/31/26) sNDA for aficamten based on MAPLE-HCM under review with FDA,

PDUFA November 14, 2026* Access to further capital: Eligible to draw up to $175M from tranche Potential for aficamten in nHCM based on positive 7 loan provided by Royalty Pharma topline results from ACACIA-HCM Approved for the treatment of

Up to $150M funding of a pivotal trial of adults with symptomatic oHCM to Expansion & breadth: CEDAR-HCM (pediatric ulacamten by Royalty Pharma at its option improve functional capacity and oHCM) enrolling, FOREST-HCM (HCM OLE) ongoing

symptoms in U.S., China & Europe Building specialty cardiology pipeline: Omecamtiv mecarbil: Ph3 confirmatory trial enrolling (COMET-HF) Ulacamten: Ph2 trial enrolling (AMBER-HFpEF) oHCM: obstructive hypertrophic cardiomyopathy; sNDA:

Supplemental New Drug Application; FDA: Food and Drug Administration; PDUFA: Prescription Drug User Fee Act; nHCM: non-obstructive hypertrophic cardiomyopathy; OLE: open label extension *The results of MAPLE-HCM showed that the mean change in pVO

from baseline to Week 24 for aficamten was +1.1 mL/kg/min and -1.2 mL/kg/min for metoprolol (least-squares mean (LSM) difference between groups of 2.3 mL/kg/min (p<0.0001) 2 MYQORZO is only approved in the U.S., China and the EU for the treatment

of adults with symptomatic oHCM. Ulacamten, omecamtiv mecarbil and CK-089 are investigational agents and have not been approved for use by any regulatory agency. Their safety and efficacy has not been established. 6

INNOVATION Advance 2 approved products across 3 indications and 10 NMEs

in our pipeline IGNITION Achieve broad access and rapid use of our medicines in >15 countries throughout North America and Europe IMPACT Reach >100,000 patients globally with our medicines INSPIRATION Foster a patient-centric culture with

emphasis on equitable access INGENUITY Extend leadership in muscle biology deploying multiple therapeutic modalities The company's Vision 2030 statements are a statement of goals and there can be no assurance that the goal indicated will be

achieved or, if achieved, will be achieved on this timeline. 7

Potential for Multiple Specialty Cardiology Launches Potential Drug 2024

2025 2026 2027 2028 2029 2030+ Indication Candidate oHCM MYQORZO oHCM Mono (aficamten) (MAPLE-HCM) nHCM (ACACIA-HCM) Omecamtiv HFrEF Mecarbil Ulacamten HFpEF Estimated date of potential future launch of each candidate for the respective indication.

The estimated launch date requires positive clinical data and regulatory approval within projected timelines. MYQORZO (aficamten) is only approved in the U.S. and China for oHCM. Ulacamten and omecamtiv mecarbil are investigational drug candidates

and are not approved as safe or effective for any indication. 8

MYQORZO (aficamten) Clinical Evidence in oHCM Prescribing Information

MYQORZO Inhibits Cardiac Myosin Motor Activity oHCM causes cardiac

MYQORZO binds to and hypercontractility, inhibits cardiac myosin, impaired cardiac relaxation & reducing cardiac contractility increased energy consumption & LVOT obstruction MYQORZO Actin Active myosin head Deactivated myosin head oHCM:

obstructive hypertrophic cardiomyopathy; LVOT: left ventricular outflow tract Please see full Prescribing Information, including Boxed WARNING and Medication Guide 1 0

SEQUOIA-HCM: Pivotal Phase 3 Trial in oHCM Significant improvement in

exercise capacity and symptoms compared to placebo Treatment with MYQORZO for 24 weeks also significantly improved: Gradients 1 -50 mmHg placebo-corrected change in post-Valsalva LVOT-G (p<0.0001) Absolute Change from Baseline to Week 24 Symptoms

MYQORZO 2 Placebo +7.9 points in KCCQ-OSS (p<0.0001) 21 2 +7.8 points in SAQ7-SS (p<0.0001) 1 34% of patients had 1 class improvement in NYHA Class (p<0.0001) 20 Disease Status 1 78 fewer days eligible for septal reduction therapy

(p<0.0001) 19 Biomarkers 1 80% reduction in NT-proBNP (p<0.001) p pV VO O = = 0 0 .0 .0 m m l/l k /g k /g m /m inin 2 2 3 43% reduction in hs-cTnI (p<0.001) 18 Structure, Function & Remodeling Improvements in maximal wall

thickness, septal wall thickness, inferolateral Baseline Week 24 wall thickness, LV mass index, LV end systolic volume index, left atrial pVO peak oxygen uptake; LS: least squares; SE: standard error; LVOT-G: left ventricular outflow tract gradient;

KCCQ-OSS: Kansas City Cardiomyopathy 2: 4 Questionnaire Overall Summary Score; SAQ7-SS: Seattle Angina Questionnaire Summary Score, NYHA: New York Heart Association; NT-pro-BNP: N-terminal volume index, lateral e' velocity, lateral E/e'

(all p<0.01) prohormone of brain natriuretic peptide: hs-cTnI: high-sensitivity cardiac troponin I; LV: left ventricular Sources: 1. Maron M. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med 2024 May

30;390(20):1849-1861 2. Sherrod C, et al. Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results from SEQUOIA-HCM. JACC. 2024. 3. Coats CJ, et al. Cardiac Biomarkers and Effects of Aficamten in Obstructive

Hypertrophic Cardiomyopathy: The SEQUOIA-HCM Trial. Eur Heart J. 2024 4. Hegde S, et al. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC. 2024. Please see full

Prescribing Information, including Boxed WARNING and Medication Guide 1 1 pVO (mL/kg/min) 2

SEQUOIA-HCM: Safety Data MYQORZO Placebo Event, n (%) (n=142) (n=140)

Overall AEs 105 (73.9) 99 (70.7) Headache 11 (7.7) 10 (7.1) Hypertension 11 (7.7) 3 (2.1) Palpitations 10 (7.0) 4 (2.9) AEs with 5% incidence Upper respiratory infection 9 (6.3) 12 (8.6) COVID-19 8 (5.6) 9 (6.4) Dyspnea 8 (5.6) 8 (5.7) There

were no serious adverse cardiovascular SAEs 8 (5.6) 13 (9.3) events associated with Cardiac AEs 24 (16.9) 21 (15.0) MYQORZO treatment in Discontinuations 5 (3.5) 4 (2.9) SEQUOIA-HCM New-onset atrial fibrillation (AF) 1 (0.7) 1 (0.7) Appropriate ICD

shock 0 1 (0.7) a LVEF <50% by core laboratory 5 (3.5) 1 (0.7) Dose reduction based on 7 (4.9) 1 (0.7) site-read LVEF <50% a 1 placebo- and 1 MYQORZO-treated patient overlap with dose reduction based on site-read LVEF <50%. AE, adverse

event; SAE, serious adverse event; ICD: implantable cardioverter defibrillator; LVEF: left ventricular ejection fraction Coats CJ. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Heart Assoc 2024 1

MAPLE-HCM: Phase 3 Monotherapy Trial in oHCM Aficamten superior to

standard-of-care beta blocker metoprolol Relative to metoprolol, aficamten also improved: Gradients Mean Change from Baseline to Week 24 in pVO 2 1 LSM difference of -30 mmHg in resting LVOT-G (p<0.0001) 1 LSM difference of -35 mmHg in

post-Valsalva LVOT-G (p<0.0001) 22 Symptoms 21 1 LSM difference of +6.9 points in KCCQ-CSS (p<0.0001) 1 51% of patients improved 1 NYHA FC (vs. 26% on metoprolol) (p<0.001) 20 Biomarkers 19 2 -81% in NT-proBNP (-73% for aficamten vs.

+42% for metoprolol) (p<0.001) 2 -28% in hs-cTnI (-43% for aficamten vs. -17% for metoprolol) (p<0.001) 18 Aficamten Metoprolol Structure, Function & Remodeling 17 2 1 LSM difference of -7.0 mL/m in left atrial volume index (p<0.0001)

Baseline Week 24 LSM difference (SE) vs. metoprolol 2.3 (0.39) mL/kg/min, P<0.0001 CI: Confidence interval; pVO peak oxygen uptake; LSM: least squares mean; KCCQ-CSS: Kansas City Cardiomyopathy Questionnaire Clinical Summary Score; NYHA FC: New

York Heart Association Functional Class; NT-pro-BNP: N-terminal prohormone of brain natriuretic 2: peptide: hs-cTnI: high-sensitivity cardiac troponin I 1. Garcia-Pavia, P, et al. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic

Cardiomyopathy. N Engl J Med. 2025 2. Lakdawala, NK et al. The Effect of Aficamten vs. Metoprolol on Cardiac Biomarkers in Obstructive Hypertrophic Cardiomyopathy. AHA 2025. MYQORZO (aficamten) is only approved in the U.S., China and the EU for the

treatment of adults with symptomatic oHCM. 1 3 Mean (95% CI) pVO (mL/kg/min) 2

MAPLE-HCM: Safety Aficamten (n=88) Metoprolol (n=87) Patients with any

SAE 7 (8.0) 6 (6.9) Patients with any AE that led to early treatment withdrawal of aficamten or 1 (1.1) 3 (3.4) a metoprolol Patients with AE that led to temporary interruption of aficamten or metoprolol 1 (1.1) 1 (1.1) b c Patients with dose

reduction due to adverse events 1 (1.1) 4 (4.6) d e Patients with 1 dose down-titration 4 (4.5) 26 (29.9) Mean (SD) change in LVEF at Week 24 vs baseline 5.3% (4.7) 0.50% (3.7) f LVEF <50% by core lab 1 (1.1) 0 Values are n

(%). a In the aficamten group, 1 patient had sudden death after a brief viral illness. In the metoprolol group, AEs leading to early treatment discontinuation are ischemic stroke, hypotension, and fractured humerus due to fall (n=1 each). b In the

aficamten group, 1 patient had a dose reduction due to an AE of dizziness. c In the metoprolol group, 4 patients had dose reduction due to AEs of lightheadedness (n=2), bradycardia (n=1), and fatigue (metoprolol, n=1). d In the aficamten group, 3

patients had 4 down-titration events based on site-read LVEF <50% (n=3) and due to an AE (n=1). e In the metoprolol group, 26 patients had 31 down-titration events based on SBP <90 mmHg (n=5), HR <50 bpm (n=17), and AE (n=4). f No

associated AE with this LVEF <50%. Garcia-Pavia, P. et al. Aficamten vs Metoprolol as Monotherapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. ESC 2025. MYQORZO (aficamten) is only approved in the U.S., China and the EU for the

treatment of adults with symptomatic oHCM. 1 4

Aficamten nHCM Prescribing Information Medication Guide 1 5

ACACIA-HCM: Pivotal Phase 3 Trial in nHCM Patients with: Trial

enrolled over 516 Aficamten Symptomatic symptomatic nHCM patients (NYHA Class II/III) nHCM, Dual primary endpoint: change KCCQ-CSS Placebo 30 and 85 in KCCQ Clinical Summary Score and peak VO2 from LVEF 60% baseline

to Week 36 NT-proBNP 300 ng/mL 5-20 mg doses; 6-week titration period Secondary endpoints: a b Part 1 Part 2 Change in Ve/VCO2 Study Visits d Titration EOT EOS Left atrial volume index (LAVI) Screen D1 W2 W4

W6 W8 W12 W24 W36 W48 W60 W72 W76 NT-proBNP c Echocardiogram Proportion of patients with 1 CPET class improvement in NYHA from KCCQ baseline to Week 36 NYHA Time to first cardiovascular event Dose Titration Biomarkers

a Part 1: All participants followed until week 36 MYQORZO is only approved in the U.S., China and the EU for the treatment of b Part 2: Participants completing Week 36 continue until either Week 72 (followed by EOS at Week 76) OR the last randomized

participant in Part 1 completes Week adults with symptomatic oHCM. 36. c Site-read focused echocardiogram for titration visit (sole criterion). Aficamten dose range 5-20 mg. d 4-week follow up after last dose 1 6 Screening Review by medical monitor

team Randomization (1:1) N = 420 Week 36 Primary Analysis KCCQ & pVO2 plus Secondary Week 72 End of Treatment (EOT) End of Study (EOS)

ACACIA-HCM: Phase 3 Trial of Aficamten in nHCM Full results to be

presented at upcoming medical meeting Change from Baseline to Week 36 Aficamten vs Placebo No new safety signals identified Primary Endpoints p-value LSM (95% CI) LSM (95% CI) % participants completing planned dosing: Aficamten Placebo Similar

between groups (88.4% on aficamten vs. 90.3% on placebo) KCCQ-CSS 11.4 (9.6 - 13.2) 8.4 (6.6 - 10.2) 3.0 (0.5 - 5.5) 0.021 LVEF <50%: 27 (10%) on aficamten vs. 2 (1%) on placebo; pVO (ml/kg/min) 0.64 (0.32 - 0.95) -0.03 (-0.35

- 0.28) 0.67 (0.22 - 1.1) 0.003 2 2 participants on aficamten had a serious adverse event of HF associated with LVEF <50% Treatment Interruptions Statistically significant (p<0.001) improvements observed in key secondary endpoints:

Treatment interruptions due to LVEF <40% 1. Proportion of participants with improvements in NYHA Functional Class occurred in 3% of patients on aficamten 2. Composite z-score of ventilatory efficiency and pVO 2 3. N-terminal pro-B-type

natriuretic peptide (NT-proBNP) nHCM: non-obstructive hypertrophic cardiomyopathy; pVO : peak oxygen uptake; LSM: least squares mean; CI: confidence interval; KCCQ-CSS: Kansas City Cardiomyopathy Questionnaire Clinical Summary Score; NYHA: New York